^
Association details:
| Biomarker: | ER D538G |
|---|---|
| Cancer: | Estrogen Receptor Positive Breast Cancer |
| Drug: | SCR-6852 (Selective estrogen receptor degrader) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
SCR-6852, an oral and highly brain-penetrating estrogen receptor degrader (SERD), effectively shrinks tumors both in intracranial and subcutaneous ER + breast cancer models
Published date:
08/14/2023
Excerpt:
The subcutaneous and intracranial ER + tumor models were used to evaluate the efficacy of anti-tumor effects....It potently inhibited cell proliferation in a panel of ER + breast cancer cell lines, including the cell lines containing ESR1 mutations (Y537 and D538)....High potency and efficacy on ER degradation and cell growth inhibition of SCR-6852 were verified in multiple ER-positive cell lines with ESR wt or mutant.
DOI:
10.1186/s13058-023-01695-4
